Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

802
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
802
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

816
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
816
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

708
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
708
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

757
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
757
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

637
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
637
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

856
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
856

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis.

Gastroenterology·2019
Same author

Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine.

Hepatology (Baltimore, Md.)·2013
Same author

Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.

Gastroenterology·2006
Same author

Circulatory function and hepatorenal syndrome in cirrhosis.

Hepatology (Baltimore, Md.)·2005
Same author

Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites.

Hepatology (Baltimore, Md.)·2005
Same author

Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding.

Hepatology (Baltimore, Md.)·2004

Related Experiment Video

Updated: Mar 30, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K

Cirrhotic cardiomyopathy.

Luis Ruiz-del-Árbol1, Regina Serradilla1

  • 1Luis Ruiz-del-Árbol, Regina Serradilla, Hepatic Hemodynamic Unit, Gastroenterology Department, Hospital Ramón y Cajal, University of Alcalá, 28034 Madrid, Spain.

World Journal of Gastroenterology
|November 12, 2015
PubMed
Summary
This summary is machine-generated.

Cirrhotic cardiomyopathy involves heart dysfunction, decreased cardiac output, and diastolic issues in cirrhosis patients. Liver transplantation may restore normal heart function.

Keywords:
Arterial blood volumeCirrhosisCirrhotic cardiomyopathyE/e’ ratioHepatorenal syndromeInotropic heart dysfunctionLeft ventricular diastolic dysfunctionLiver failure

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.5K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.1K

Related Experiment Videos

Last Updated: Mar 30, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.5K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.1K

Area of Science:

  • Cardiology
  • Hepatology
  • Internal Medicine

Background:

  • Cirrhosis leads to progressive cardiac dysfunction, including loss of hyperdynamic circulation and decreased cardiac output.
  • This cardiac deterioration involves impaired inotropic and chronotropic function, diastolic dysfunction, and cardiac hypertrophy, independent of other heart diseases.

Purpose of the Study:

  • To describe the characteristics and pathogenic mechanisms of cirrhotic cardiomyopathy.
  • To highlight diagnostic challenges and potential monitoring tools for cirrhotic cardiomyopathy.
  • To elucidate the clinical consequences and prognostic implications of cirrhotic cardiomyopathy.

Main Methods:

  • Review of existing literature on cirrhotic cardiomyopathy.
  • Discussion of diagnostic methods, including echocardiography and the E/e' ratio.
  • Exploration of pathogenic mechanisms such as beta-adrenergic signaling impairment and ion channel defects.

Main Results:

  • Cirrhotic cardiomyopathy presents with impaired contractile responsiveness and electrophysiological abnormalities like prolonged QT interval.
  • Mechanisms include impaired beta-adrenergic signaling, altered cardiomyocyte membrane properties, ion channel defects, and cardiodepressant factors.
  • Echocardiography, particularly the E/e' ratio, aids in detecting diastolic dysfunction and monitoring disease progression.

Conclusions:

  • Cirrhotic cardiomyopathy significantly contributes to impaired arterial blood volume and correlates with liver failure severity.
  • Cardiac dysfunction can lead to renal hypoperfusion and renal failure.
  • While treatment is non-specific, liver transplantation offers potential for normalizing cardiac function.